LENZ Therapeutics

LENZNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$168.060 M

$5.36 +2.68%

Close of 7 Aug 2026

Revenue

$19.1M

#3017 by revenue

Earnings

-$82.1M

Loss-making

Shares outstanding

31,354,394

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#101Acumen PharmaceuticalsABOS$176.2M
#102Armata PharmaceuticalsARMP$172.9M
#103LENZ TherapeuticsLENZ$168.1M
#104Cardiol TherapeuticsCRDL$163.7M
#105Caribou BiosciencesCRBU$163.6M

Where these numbers come from

Share counts and financials for LENZ Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.